The Altiora Perspective

The Phone Call That Changed Everything

Part 4 – How a Financial Crisis Reshaped Clinical Research

I still remember the date.

31 January 2013.

The phone rang.

It was a landline, back when most important business conversations still happened that way.

On the other end was a manager from one of the world's largest pharmaceutical companies. We had worked together for years. At the time, Altiora ranked among their three largest regional CRO partners. Our inspections had been flawless. Our projects were running well. The relationship was excellent.

Yet I didn't recognise the voice. Later I understood why. The people I knew simply couldn't bring themselves to make that call.

He delivered the news calmly.

Within three months, every ongoing project had to be transferred to a global CRO.

I was speechless. Not because we had lost the business. But because I couldn't imagine how it would even be possible to transfer so many studies safely in such a short time.

Somehow, we did.

It Was Never About Performance

Looking back, I realise something important. We hadn't failed. There had been no critical findings. No quality issues. No damaged relationship.

The decision had been made thousands of kilometres away, in boardrooms where people looked at portfolios rather than partnerships.

I had heard rumours that the industry was changing. Still, I believed our projects would remain with us until completion. After all, continuity is valuable in clinical research.

I was wrong. The rules had changed.

A Crisis Few People Connected to Clinical Research

Most people remember the financial crisis of 2008 for what it did to banks, financial markets and real estate. Few realise how profoundly it changed pharmaceutical research. The first wave barely affected large pharmaceutical companies.

Patients still needed medicines.

Clinical development continued.

But as the recession deepened through 2009, 2010 and into 2011, companies inevitably began asking the same question every business asks during difficult times.

Where can we reduce costs?

The answer was uncomfortable. Research and development.

At the time, bringing a single medicine to market was estimated to cost between 700 and 800 million US dollars, while only about one in ten development programmes would ever succeed. Every successful medicine had to pay not only for itself, but also for the nine that never reached patients. Meanwhile, governments and healthcare systems were demanding lower drug prices.

Innovation became increasingly difficult to finance.

When Regulation Meets Reality

Long before artificial intelligence became fashionable, regulators recognised that clinical research needed to become more efficient. In 2011, the FDA published guidance that fundamentally changed how clinical trials could be monitored.

Its message was refreshingly pragmatic.

The industry had gradually convinced itself that monitoring every site every four to six weeks represented good quality. The regulations never actually said that. Good Clinical Practice requires sponsors to ensure participant safety and data integrity. It does not prescribe how frequently monitors should visit every investigator site.

The FDA encouraged companies to think differently. Use technology. Monitor data centrally. Identify trends. Focus resources where the risks are greatest instead of treating every site the same.

That guidance became the foundation of what we now know as risk-based monitoring.

Looking back, it marked the beginning of modern, technology-enabled clinical operations.

The End of One Business Model

The regulatory shift coincided perfectly with economic pressure. Consultants began encouraging pharmaceutical companies to move away from managing numerous regional vendors towards long-term strategic partnerships with a handful of global CROs. The logic was difficult to argue against.

If you're building your family's dream home, you'll probably choose individual craftsmen for every detail. You'll personally select them. Interview them. Explain exactly how you want everything done. It takes time, but you stay in complete control.

If you're building hundreds of houses as a commercial developer, you'll probably choose a turnkey contractor instead. One company. One contract. One point of accountability. Less coordination. Greater scale.

Clinical research followed the same path.

Large pharmaceutical companies reduced their regional operational teams and outsourced increasingly larger parts of clinical development to global CROs.

The race towards digitalisation had begun.

Reinventing Ourselves

For regional CROs, survival meant reinventing ourselves. We could never compete with global organisations on size.

So we focused on something different.

Smaller and emerging pharmaceutical companies.

These organisations often had outstanding scientific ideas but limited operational resources. Their programmes were few. Every study mattered. Every delay mattered. They wanted more than a vendor. They wanted a partner.

Sometimes we managed studies. Sometimes we helped build their clinical development capabilities from the ground up. In many ways, we became an extension of their own organisation.

Learning Flexibility

The business became less predictable. Projects ended. New ones appeared. Teams expanded. Then contracted again. Managing uncertainty became part of everyday life. It wasn't easy. But it taught us something invaluable. Flexibility is not about changing direction every day. It's about adapting without losing your identity.

Some Things Never Changed

Technology transformed clinical research. Business models evolved. Partnership structures changed. The industry became larger, faster and more sophisticated.

Yet one thing remained exactly the same.

Clients still choose people they trust. People still follow leaders who communicate honestly. Teams still succeed because they care about one another and companies still survive because they never stop learning.

That lesson has remained true through every crisis I have experienced.

The Altiora Perspective

A personal reflection by Josip Aralica, MD, Founder & CEO of Altiora.